Malaria vaccine development entered a new era in 2015 when the pre-erythrocytic
Plasmodium falciparum candidate RTS, S was favorably reviewed by the European …

Background The world has made great strides towards beating malaria, although about half
of the world population is still exposed to the risk of contracting malaria. Developing an …

There are no licensed vaccines against Plasmodium vivax. We conducted two phase 1/2a
clinical trials to assess two vaccines targeting P. vivax Duffy-binding protein region II …

Background PRIMVAC is a VAR2CSA-derived placental malaria vaccine candidate aiming
to prevent serious clinical outcomes of Plasmodium falciparum infection during pregnancy …

Plasmodium vivax infection, the predominant cause of malaria in Asia and Latin America,
affects~ 14 million individuals annually, with considerable adverse effects on wellbeing and …

Malaria is one of the most devastating human infectious diseases caused by Plasmodium
spp. parasites. A search for an effective and safe vaccine is the main challenge for its …

Tackling relapsing Plasmodium vivax and zoonotic Plasmodium knowlesi infections is
critical to reducing malaria incidence and mortality worldwide. Understanding the biology of …

Fast and effective detection of the causative agent of malaria in humans, protozoan
Plasmodium parasites, is of crucial importance for increasing the effectiveness of treatment …

Malaria remains one of the biggest health problems in the world. While significant reductions
in malaria morbidity and mortality had been achieved from 2000 to 2015, the favorable trend …

Controlled human malaria infection (CHMI) provides a highly informative means to
investigate host-pathogen interactions and enable in vivo proof-of-concept efficacy testing of …